| Literature DB >> 23538115 |
Balasubramanian Gopalan1, Thanasekaran Ponpandian, Virendra Kachhadia, Kuppusamy Bharathimohan, Radhakrishnan Vignesh, Velaiah Sivasudar, Shridhar Narayanan, Bhonde Mandar, Rajendran Praveen, Nithyanandan Saranya, Sriram Rajagopal, Sridharan Rajagopal.
Abstract
Herein, we report the development of highly potent HDAC inhibitors for the treatment of cancer. A series of adamantane and nor-adamantane based HDAC inhibitors were designed, synthesized and screened for the inhibitory activity of HDAC. A number of compounds exhibited GI50 of 10-100 nM in human HCT116, NCI-H460 and U251 cancer cells, in vitro. Compound 32 displays efficacy in human tumour animal xenograft model.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23538115 DOI： 10.1016/j.bmcl.2013.03.002
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823